The state of Illinois currently has 24 active clinical trials seeking participants for Multiple Sclerosis research studies. These trials are conducted in various cities, including Chicago, Peoria, Springfield and Urbana.
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Recruiting
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion crite... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
06/21/2024
Locations: Consultants In Neurology Site Number : 8400020, Northbrook, Illinois +1 locations
Conditions: Multiple Sclerosis
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: This event... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
06/20/2024
Locations: NorthShore University Healthsystem Site Number : 8401111, Evanston, Illinois +2 locations
Conditions: Multiple Sclerosis
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
06/17/2024
Locations: Consultants In Neurology, Northbrook, Illinois
Conditions: Multiple Sclerosis
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Northwestern University, Chicago, Illinois +1 locations
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis
Recruiting
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over a duration of at least 96 weeks.
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
06/05/2024
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Relapsing-Remitting Multiple Sclerosis
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Recruiting
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/21/2024
Locations: Rush University Medical Center, Chicago, Illinois +1 locations
Conditions: Relapsing Multiple Sclerosis
An Individualized-health eLibrary App for People With Multiple Sclerosis
Recruiting
The purpose of this study is to assess the effectiveness after using a new individualized-health e-library app named SavvyHealth among people with multiple sclerosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: University of Illinois Urbana-Champaign, Champaign, Illinois
Conditions: Multiple Sclerosis
A Health Action Process Approach Online Intervention for People With Multiple Sclerosis
Recruiting
The purpose of this study is to implement the person-centered internet-based Health Action Process Approach to promoting physical activity in people with Multiple Sclerosis (i.e., eHAPA-MS online intervention) and assess the intervention's effectiveness and adherence.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: University of Illinois Urbana-Champaign, Champaign, Illinois
Conditions: Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
05/07/2024
Locations: Rush University Medical Center CFTY720D2312, Chicago, Illinois +3 locations
Conditions: Relapsing Multiple Sclerosis
Effects of High-intensity Gait Training on Fatigue, Gait, and Neuroplasticity in People With Multiple Sclerosis
Recruiting
Nearly 1 million individuals in the United States have multiple sclerosis, which causes fatigue and problems with walking. Fatigue and walking problems are poorly treated, but exercise training, particularly high-intensity walking exercise, may help. This provide insight into whether high-intensity walking exercise can improve fatigue and walking problems in people with multiple sclerosis, which could improve quality of life and reduce economic burden.
Gender:
All
Ages:
21 years and above
Trial Updated:
05/06/2024
Locations: University of Illinois Chicago, Chicago, Illinois
Conditions: Multiple Sclerosis
Lifestyle Physical Activity Intervention for Persons Newly Diagnosed With Multiple Sclerosis
Recruiting
The overall objective of the current study is to determine the efficacy of a 16-week remotely delivered lifestyle behavioral intervention compared with a control condition (i.e., waitlist control) in persons newly diagnosed with MS (disease duration ≤ 2 years). Specific Aim 1: To evaluate the changes in self-report and device-measured physical activity after the 16-week remotely delivered physical activity behavior change intervention compared with a control condition (i.e., waitlist control) i... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/06/2024
Locations: University of Illinois Chicago, Chicago, Illinois
Conditions: Multiple Sclerosis
Feasibility of Remote Exercise Training for Hispanics/Latinos With MS
Recruiting
The goal of this clinical trial is to investigate the potential benefits of a specially designed exercise program for Hispanics/Latinos with multiple sclerosis (MS). The main questions it aims to answer are: Can a 4-month remotely-delivered exercise training program improve physical function, symptom management, and quality of life in Hispanics/Latinos with MS? How do social determinants of health, such as income, education, access to healthcare, and social support, influence the feasibility an... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/05/2024
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Multiple Sclerosis